Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Non-Small Cell Lung Cancer

21 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    ECOGTHOA151216

    09/17/2015

    Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

    Basic Science

    VICCMEL15137

    07/21/2015

    Characterizing the Cardiometabolic Implications of Immune Therapy

    Basic Science

    VICCTHO0398

    12/04/2003

    Molecular Predictors of Lung Cancer Behavior. (SPORE)

    Basic Science

    VICCTHO0136

    05/01/2001

    Molecular Fingerprinting of Lung Cancer (SPORE)

    Treatment

    VICCMD1763

    11/14/2017

    A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

    Treatment

    VICCMD16159

    11/07/2017

    A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination with Pembrolizumab and Epacadostat in Subjects with Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non?Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer

    Treatment

    VICCMD1710

    08/03/2017

    A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination with a PD-1 Inhibitor and Chemotherapy in Subjects with Advanced or Metastatic Solid Tumors (ECHO-207)

    Treatment

    VICCTHO1684

    07/20/2017

    Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation Positive NSCLC with Acquired Resistance to First or Third Generation EGFR TKIs

    Treatment

    VICCTHO16139

    06/13/2017

    A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

    Treatment

    VICCTHO1722

    05/26/2017

    Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin

    Treatment

    VICCTHO16148

    05/25/2017

    A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

    Treatment

    VICCMD1636

    12/21/2016

    A Phase 1b/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

    Treatment

    VICCMD1649

    12/14/2016

    A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer

    Treatment

    VICCPHI1676

    11/04/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects with Advanced or Metastatic Solid Tumors

    Treatment

    VICCPHI1634

    08/30/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

    Treatment

    VICCTHO1614

    08/05/2016

    A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

    Treatment

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

    Treatment

    VICCTHO1478

    11/14/2014

    A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

    Treatment

    ECOGTHO5508-M

    02/09/2011

    Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

    Treatment

    ECOGTHOE1505-M

    07/27/2007

    A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)


    Print this page for your doctor